» Articles » PMID: 12966153

Peroxisome Proliferator-activated Receptor-gamma Activator 15-deoxy-Delta12,14-prostaglandin J2 Inhibits Neuroblastoma Cell Growth Through Induction of Apoptosis: Association with Extracellular Signal-regulated Kinase Signal Pathway

Overview
Specialty Pharmacology
Date 2003 Sep 11
PMID 12966153
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands have been demonstrated to inhibit growth of several cancer cells. Here, we investigated whether one of the PPAR-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 (15-deoxy-PGJ2) inhibits cell growth of two human neuroblastoma cells (SK-N-SH and SK-N-MC) in a PPAR-gamma-dependent manner. PPAR-gamma was expressed in these cells, and 15-deoxy-PGJ2 increased expression, DNA binding activity, and transcriptional activity of PPAR-gamma. 15-Deoxy-PGJ2 also inhibited cell growth in time- and dose-dependent manners in both cells. Cells were arrested in G2/M phase after 15-deoxy-PGJ2 treatment with concomitant increase in the expression of G2/M phase regulatory protein cyclin B1 but decrease in the expression of cdk2, cdk4, cyclin A, cyclin D1, cyclin E, and cdc25C. Conversely, related to the growth inhibitory effect, 15-deoxy-PGJ2 increased the induction of apoptosis in a dose-dependent manner. Consistent with the induction of apoptosis, 15-deoxy-PGJ2 increased the expression of proapoptotic proteins caspase 3, caspase 9, and Bax but down-regulated antiapoptotic protein Bcl-2. 15-Deoxy-PGJ2 also activated extracellular signal-regulated kinase (ERK) 2. In addition, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor PD98059 (2'-amino-3'-methoxyflavone) decreased 15-deoxy-PGJ2-induced ERK2 activation, and expression of PPAR-gamma, capase-3, and cyclin B1. Moreover, MEK1/2 inhibitor PD98059 significantly prevented against the 15-deoxy-PGJ2-induced cell growth inhibition. We also found that PPAR-gamma antagonist GW9662 (2-chloro-5-nitro-N-phenylbenzamide) reversed the 15-deoxy-PGJ2-induced cell growth inhibition, PPAR-gamma expression, and activation of ERK2. These results demonstrate that 15-deoxy-PGJ2 inhibits growth of human neuroblastoma cells via the induction of apoptosis in a PPAR-gamma-dependent manner through activation of ERK pathway and suggest that 15-deoxy-PGJ2 may have promising application as a therapeutic agent for neuroblastoma.

Citing Articles

A signature based on five immune-related genes to predict the survival and immune characteristics of neuroblastoma.

Ma K, Zhang P, Xia Y, Dong L, Li Y, Liu L BMC Med Genomics. 2022; 15(1):242.

PMID: 36419120 PMC: 9685875. DOI: 10.1186/s12920-022-01400-y.


Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Wagner N, Wagner K Cells. 2022; 11(15).

PMID: 35954274 PMC: 9368267. DOI: 10.3390/cells11152432.


Synergistic effects of 15-deoxy Δ-prostaglandin J on the anti-tumor activity of doxorubicin in renal cell carcinoma.

Yamamoto Y, Yamamoto T, Koma H, Nishii A, Yagami T Biochem Biophys Rep. 2017; 9:61-66.

PMID: 28955990 PMC: 5614541. DOI: 10.1016/j.bbrep.2016.11.004.


A Model for Spheroid versus Monolayer Response of SK-N-SH Neuroblastoma Cells to Treatment with 15-Deoxy-.

Wallace D, Dunham A, Chen P, Chen M, Huynh M, Rheingold E Comput Math Methods Med. 2017; 2016:3628124.

PMID: 28044089 PMC: 5156871. DOI: 10.1155/2016/3628124.


PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs.

Vella S, Conaldi P, Florio T, Pagano A PPAR Res. 2016; 2016:3038164.

PMID: 27799938 PMC: 5069360. DOI: 10.1155/2016/3038164.